What are the major opportunities in the Minimal Residual Disease market? What are the strategies for the Minimal Residual Disease market?

For detailed insights on the major opportunities and strategies in the Minimal Residual Disease market, Read More

How does the Minimal Residual Disease market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Minimal Residual Disease market growth and SWOT analysis of the Minimal Residual Disease industry, Read More

For detailed insights on the mergers and acquisitions in the Minimal Residual Disease industry,

What are the key dynamics influencing the Minimal Residual Disease market growth? SWOT analysis of the Minimal Residual Disease market. Read More

Global Minimal Residual Disease Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

Minimal Residual Disease Global Market Report 2025

Name: Minimal Residual Disease Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Detection Target (Lymphoma, Leukemia, Solid Tumors, Other Detection Targets), By Test Technique (Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques), By End-User (Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Minimal Residual Disease Market Overview

• Minimal Residual Disease market size has reached to $1.78 billion in 2024

• Expected to grow to $3.19 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%

• Growth Driver: Rising Cancer Prevalence Driving Growth In The Market

• Market Trend: Advanced In Vitro Diagnostic (IVD) Test Services For Minimal Residual Disease (MRD) Detection In Diffuse Large B-Cell Lymphoma

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Minimal Residual Disease Market?

Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse.

The main types of detection targets for minimal residual disease are lymphoma, leukemia, solid tumors, and others. Lymphoma is a cancer originating in the lymphatic system, primarily targeting white blood cells known as lymphocytes. The various test techniques include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others and are used by several end-users, including banking, financial services, and insurance (BFSI), retail and e-commerce, hospitals, diagnostic laboratories, and research institutions.

Minimal Residual Disease Market Size and growth rate 2025 to 2029: Graph

What Is The Minimal Residual Disease Market Size 2025 And Growth Rate?

What Is The Minimal Residual Disease Market Growth Forecast?

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.19 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to rise in the number of patients with cancer, rise in the government awareness programs, rise in the healthcare affordability, increasing disposable income in emerging economies, and government body initiatives to create awareness about cancer. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, adoption of personalized MRD monitoring, development in liquid biopsy technologies, minimal residual disease-directed therapies.

The forecast of 12.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer monitoring by inflating prices of next-generation sequencing panels and digital Polymerase Chain Reaction(PCR) systems developed in Switzerland and South Korea, resulting in delayed relapse detection and higher oncology testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Minimal Residual Disease Market Segmented?

1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets

2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques

3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions

Subsegments:

1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma

2) By Leukemia: Acute Lymphoblastic Leukemia, acute myeloid leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia

3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas

What Is Driving The Minimal Residual Disease Market? Rising Cancer Prevalence Driving Growth In The Market

The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to factors such as an aging population, increased exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising cancer prevalence increases the demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This improves relapse prediction and enhances patient outcomes. For instance, in May 2024, according to the National Cancer Institute (NCI), a US-based government agency, in 2022 nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease industry.

Who Are The Major Players In The Global Minimal Residual Disease Market?

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

What Are The Key Trends Of The Global Minimal Residual Disease Market? Advanced In Vitro Diagnostic (IVD) Test Services For Minimal Residual Disease (MRD) Detection In Diffuse Large B-Cell Lymphoma

Major companies operating in the minimal residual disease (MRD) market are focusing on developing advanced in vitro diagnostic (IVD) test services to provide personalized therapy options for better patient outcomes. An in vitro diagnostic (IVD) test service is a lab-based diagnostic method to detect residual cancer cells after treatment, helping predict relapse and optimize therapy. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, launched clonoSEQ Assay to detect minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples to provide a highly sensitive, non-invasive way to monitor cancer progression and detect early signs of relapse. This assay offers clinicians a more precise understanding of a patient’s disease burden, helping them tailor treatment plans accordingly. It is the first minimal residual disease (MRD) test for diffuse large B-cell lymphoma (DLBCL) to receive Medicare coverage, making it widely accessible across all treatment regimens and time points.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Minimal Residual Disease Market? Veracyte Acquired C2i Genomics To Enhance Cancer Diagnostics With MRD Expertise

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. The acquisition integrates C2i Genomics' whole-genome minimal residual disease (MRD) expertise into Veracyte's diagnostic platform, strengthening its capacity to support patients across all stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company that provides a minimal residual disease (MRD) test.

What Is The Regional Outlook For The Global Minimal Residual Disease Market?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Minimal Residual Disease Market?

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Minimal Residual Disease Industry?

The minimal residual disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Minimal Residual Disease Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$2.01 billion
Revenue Forecast In 2034	$3.19 billion
Growth Rate	CAGR of 12.3% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The minimal residual disease market covered in this report is segmented – 1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets 2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques 3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions Subsegments: 1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma 2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia 3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer 4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Minimal Residual Disease Market Characteristics

3. Minimal Residual Disease Market Trends And Strategies

4. Minimal Residual Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Minimal Residual Disease Growth Analysis And Strategic Analysis Framework

5.1. Global Minimal Residual Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Minimal Residual Disease Market Growth Rate Analysis

5.4. Global Minimal Residual Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Minimal Residual Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Minimal Residual Disease Total Addressable Market (TAM)

6. Minimal Residual Disease Market Segmentation

6.1. Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lymphoma

Leukemia

Solid Tumors

Other Detection Targets

6.2. Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next Generation Sequencing (NGS)

Other Test Techniques

6.3. Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Banking, Financial Services, And Insurance (BFSI)

Retail And E-Commerce

Hospitals

Diagnostic Laboratories

Research Institutions

6.4. Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

6.5. Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

6.6. Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

6.7. Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Multiple Myeloma

Neuroblastoma

Sarcom

7. Minimal Residual Disease Market Regional And Country Analysis

7.1. Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Minimal Residual Disease Market

8.1. Asia-Pacific Minimal Residual Disease Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Minimal Residual Disease Market

9.1. China Minimal Residual Disease Market Overview

9.2. China Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Minimal Residual Disease Market

10.1. India Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Minimal Residual Disease Market

11.1. Japan Minimal Residual Disease Market Overview

11.2. Japan Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Minimal Residual Disease Market

12.1. Australia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Minimal Residual Disease Market

13.1. Indonesia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Minimal Residual Disease Market

14.1. South Korea Minimal Residual Disease Market Overview

14.2. South Korea Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Minimal Residual Disease Market

15.1. Western Europe Minimal Residual Disease Market Overview

15.2. Western Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Minimal Residual Disease Market

16.1. UK Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Minimal Residual Disease Market

17.1. Germany Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Minimal Residual Disease Market

18.1. France Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Minimal Residual Disease Market

19.1. Italy Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Minimal Residual Disease Market

20.1. Spain Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Minimal Residual Disease Market

21.1. Eastern Europe Minimal Residual Disease Market Overview

21.2. Eastern Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Minimal Residual Disease Market

22.1. Russia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Minimal Residual Disease Market

23.1. North America Minimal Residual Disease Market Overview

23.2. North America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Minimal Residual Disease Market

24.1. USA Minimal Residual Disease Market Overview

24.2. USA Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Minimal Residual Disease Market

25.1. Canada Minimal Residual Disease Market Overview

25.2. Canada Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Minimal Residual Disease Market

26.1. South America Minimal Residual Disease Market Overview

26.2. South America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Minimal Residual Disease Market

27.1. Brazil Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Minimal Residual Disease Market

28.1. Middle East Minimal Residual Disease Market Overview

28.2. Middle East Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Minimal Residual Disease Market

29.1. Africa Minimal Residual Disease Market Overview

29.2. Africa Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Minimal Residual Disease Market Competitive Landscape And Company Profiles

30.1. Minimal Residual Disease Market Competitive Landscape

30.2. Minimal Residual Disease Market Company Profiles

30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Laboratory Corporation of America Holdings (LabCorp) Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Minimal Residual Disease Market Other Major And Innovative Companies

31.1. Sysmex Corporation

31.2. Bio-Rad Laboratories Inc.

31.3. Qiagen N.V.

31.4. Exact Sciences Corporation

31.5. Kite Pharma Inc.

31.6. Natera Inc.

31.7. Foundation Medicine Inc.

31.8. NeoGenomics Inc.

31.9. Guardant Health Inc.

31.10. Grail LLC

31.11. Tempus AI Inc.

31.12. Veracyte Inc.

31.13. Adaptive Biotechnologies Corporation

31.14. Invivoscribe Inc.

31.15. Mission Bio Inc.

32. Global Minimal Residual Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Market

34. Recent Developments In The Minimal Residual Disease Market

35. Minimal Residual Disease Market High Potential Countries, Segments and Strategies

35.1 Minimal Residual Disease Market In 2029 - Countries Offering Most New Opportunities

35.2 Minimal Residual Disease Market In 2029 - Segments Offering Most New Opportunities

35.3 Minimal Residual Disease Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Thermo Fisher Scientific Inc. Financial Performance

Table 79: Amgen Inc. Financial Performance

Table 80: Laboratory Corporation of America Holdings (LabCorp) Financial Performance

Table 81: Quest Diagnostics Incorporated Financial Performance

Table 82: Agilent Technologies Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Thermo Fisher Scientific Inc. Financial Performance

Figure 79: Amgen Inc. Financial Performance

Figure 80: Laboratory Corporation of America Holdings (LabCorp) Financial Performance

Figure 81: Quest Diagnostics Incorporated Financial Performance

Figure 82: Agilent Technologies Inc. Financial Performance

Top Trends Driving Innovation and Change in the Interstitial Lung Disease Market: Innovative Drug Development Initiatives To Improve Interstitial Lung Disease Treatment

Global Intestinal Pseudo-Obstruction Treatment Market Projected to Reach $30.8 Billion by 2029 at a CAGR of 5.6%

Key Developments and Trends Steering the Intestine Cancer Therapeutics Market Forward: Increasing Focus On Product Approvals To Drive The Revenues

Major Trends and Emerging Patterns in the Intravenous Solutions Market: Innovative Syringes Transforming The Intravenous Solutions Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Explore the latest trends, growth insights, and forecasts in the Nutrition Analysis Software Global Market.

Rare Disease Diagnostics Global Market Report 2025 – By Test Type (Genetic Test, General Lab Test, Imaging Test), By Technology (Capillary Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays), By Sam...

Rare Diseases Treatment Global Market Report 2025 – By Drug Type( Originator Drugs (Patented Molecules), Generic Drugs), By Drug Class( Biologics, Organic Compounds), By Mode Of Administration( Injectable, Oral, Other Mo...

Rare Neurological Disease Treatment Global Market Report 2025 – By Drug Type (Biologics, Small Molecules), By Therapy (Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies), By Mode Of A...

Rare Inflammatory Disease Treatment Global Market Report 2025 – By Drug Class (Biologics, Organic Compounds), By Mode Of Administration (Injectables, Oral, Other Administration Modes), By Indication (Ulcerative Colitis, ...

Rare Kidney Diseases Global Market Report 2025 – By Target Indication (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications), By Type...

Erdheim Chester Disease Global Market Report 2025 – By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Other Treatments), By Route of Administration (oral, Parenteral, Other Route Of Administration), By Distri...

Primary Care POC Diagnostics Global Market Report 2025 – By Product (Glucose Monitoring, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy And Fertility Testin...

Frequently Asked Questions

What is the definition of the Minimal Residual Disease market?

How will the Minimal Residual Disease market drivers and restraints affect the market dynamics? What forces will shape the Minimal Residual Disease industry going forward?

The market major growth driver - Rising Cancer Prevalence Driving Growth In The Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Minimal Residual Disease market?

The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increasing number of cancer patients, growing research and development spending, rising healthcare affordability, rising prevalence of blood cancer, and increasing awareness among people. The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to " $3.19 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to rise in the number of patients with cancer, rise in the government awareness programs, rise in the healthcare affordability, increasing disposable income in emerging economies, and government body initiatives to create awareness about cancer. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, adoption of personalized MRD monitoring, development in liquid biopsy technologies, minimal residual disease-directed therapies. For further insights on this market, request a sample here

How is the Minimal Residual Disease market segmented?

The minimal residual diseasemarket covered in this report is segmented –
1) By Detection Target: Lymphoma; Leukemia; Solid Tumors; Other Detection Targets
2) By Test Technique: Flow Cytometry; Polymerase Chain Reaction (PCR); Next Generation Sequencing (NGS); Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI); Retail And E-Commerce; Hospitals; Diagnostic Laboratories; Research Institutions Subsegments:
1) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma; Neuroblastoma; Sarcomas For further insights on this market, request a sample here

Which region has the largest share of the Minimal Residual Disease market? What are the other regions covered in the report?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Minimal Residual Disease market?

What are the key trends in the Minimal Residual Disease market?

Major trends in this market include Advanced In Vitro Diagnostic (IVD) Test Services For Minimal Residual Disease (MRD) Detection In Diffuse Large B-Cell Lymphoma. For further insights on this market, request a sample here.